MSAA: Publications - The Motivator: Summer/Fall 2012 - Cover Story: Fred D. Lublin, MD, FAAN
Multiple Sclerosis Association of America Logo
Link to FaceBook Link to Twitter Link to YouTube Link to Pinterest
Register Why Register Contact MSAA Site Preferences Print Page Home
Improving Lives Today!
Donate Button
The Motivator iconMSAA's MAGAZINE
The Motivator
Booklets and Brochures iconBooklets & Brochures
MS Research Update 2015
MS Research Update 2014
About MS
Improving Lives Today! A Guide
to MSAA's Programs and Services
Ways to Give
Medicare Planning
and Multiple Sclerosis
The Affordable Care Act
and Multiple Sclerosis
Aquatic Exercise and Multiple Sclerosis:
A Guide for Patients
How to S.E.A.R.C.H.™ for the Right
MS Therapy for You!
Understanding and Treating
MS Relapses
Mommy's Story
Daddy's Story
Understanding and Treating
Depression in Multiple Sclerosis
MSAA Monograph: The Confusing
World of Clinical Trials
Primary Progressive Multiple
Sclerosis: What You Need to Know
Order Publications iconOrder Publications
Individual Order
Group Orders

Home > MSAA Publications > The Motivator > The Motivator: Summer/Fall 2012 > Cover Story: The Evolution of MS Diagnosis, Treatment, and Care > Fred D. Lublin, MD, FAAN
Share this Page:
submit to reddit

Back - Home - Next

Photo of Fred D. Lublin, MD, FAAN

Fred D. Lublin, MD, FAAN

Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine, New York

...on the development of disease-modifying therapies

"The field of MS therapeutics has been at the leading edge of innovative research into the treatment of neurologic illness. Having nine disease-modifying agents, and a full pipeline of newer molecules that may prove successful in the treatment of MS, have transformed the care of MS.

"We have developed successful clinical trial designs that have provided the validated evidence of efficacy (proof of effectiveness) that is critical for moving the field forward. We will leverage our past and current successes into better future therapies for MS. These include the treatment of progressive disease and the development of strategies for repair of the damaged central nervous system (CNS).

"Several late-phase clinical trials aimed at treating progressive forms of MS are currently underway, as is the early-phase testing of stem cells for potential repair of damaged nerves. New initiatives in treating the symptoms of MS have also yielded encouraging results. Overall, the future for improving the lives of individuals with MS has never looked brighter."

As a neuroimmunologist, Dr. Fred D. Lublin has a special interest in immune functions and abnormalities affecting the CNS. He is currently involved with several new clinical research protocols on promising agents for treating MS. He has been either a member or chair of many MS committees, professional societies, and advisory boards. Dr. Lublin has published numerous scientific articles and is the co-chief editor of the new journal, Multiple Sclerosis and Related Diseases. He has served as a consultant to the NIH and to many pharmaceutical/biotech companies in all phases of new drug development. He is the principal investigator of the NIH-sponsored multicenter Combination Therapy study in MS.

Back - Home - Next

Last Updated on Tuesday, 12 March 2013 15:38